Empowered Funds LLC lessened its holdings in Pediatrix Medical Group, Inc. (NYSE:MD – Free Report) by 4.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 595,510 shares of the company’s stock after selling 26,870 shares during the quarter. Empowered Funds LLC owned approximately 0.73% of Pediatrix Medical Group worth $12,738,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of MD. Wasatch Advisors LP bought a new position in Pediatrix Medical Group in the first quarter valued at approximately $43,861,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Pediatrix Medical Group during the fourth quarter worth $13,613,000. Rockefeller Capital Management L.P. grew its stake in shares of Pediatrix Medical Group by 814.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 594,351 shares of the company’s stock worth $12,713,000 after purchasing an additional 529,367 shares during the period. Ameriprise Financial Inc. lifted its stake in Pediatrix Medical Group by 175.4% in the second quarter. Ameriprise Financial Inc. now owns 744,473 shares of the company’s stock valued at $10,683,000 after buying an additional 474,186 shares during the period. Finally, BNP Paribas Financial Markets boosted its holdings in Pediatrix Medical Group by 669.4% during the second quarter. BNP Paribas Financial Markets now owns 476,098 shares of the company’s stock worth $6,832,000 after buying an additional 414,216 shares during the last quarter. 97.71% of the stock is owned by institutional investors.
Insider Buying and Selling at Pediatrix Medical Group
In other news, Director Shirley A. Weis sold 36,028 shares of Pediatrix Medical Group stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $23.75, for a total value of $855,665.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.80% of the stock is owned by corporate insiders.
Pediatrix Medical Group Trading Down 0.4%
Pediatrix Medical Group (NYSE:MD – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The firm had revenue of $476.20 million during the quarter, compared to analysts’ expectations of $465.83 million. Pediatrix Medical Group had a return on equity of 19.94% and a net margin of 9.02%.The company’s revenue was up 3.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.33 EPS. As a group, research analysts forecast that Pediatrix Medical Group, Inc. will post 2.1 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on MD. Truist Financial upped their price target on Pediatrix Medical Group from $23.00 to $28.00 and gave the company a “hold” rating in a research note on Tuesday, July 14th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $27.00 target price on shares of Pediatrix Medical Group in a research note on Monday, April 20th. Mizuho set a $24.00 price target on shares of Pediatrix Medical Group in a research report on Friday, May 8th. Weiss Ratings restated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research report on Wednesday, June 24th. Finally, UBS Group lifted their target price on Pediatrix Medical Group from $22.00 to $25.00 and gave the stock a “neutral” rating in a report on Tuesday, May 12th. One investment analyst has rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $23.33.
View Our Latest Research Report on MD
Pediatrix Medical Group Company Profile
Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.
Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.
Featured Stories
- Five stocks we like better than Pediatrix Medical Group
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Pediatrix Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediatrix Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.
